Approval · Notice of Compliance 18528 · 2016
MINT-CLOPIDOGREL: Notice of Compliance 18528
Issued September 29, 2016
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 18528
- Date
- September 29, 2016
- Company
- Mint Pharmaceuticals IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Change in specifications
- Canadian reference product
- PLAVIX (Sanofi-Aventis Canada Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MINT-CLOPIDOGREL | Not yet assigned | — |
Medicinal ingredients
- CLOPIDOGREL BISULFATE 75 MG per TAB
- CLOPIDOGREL BISULFATE 300 MG per TAB